reference/9947999

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/9947999

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase II\|Journal Article\|Multicenter Study\|Randomized Controlled Trial\|Research Support, Non-U.S. Gov't
endingPage	344
issn	1468-1293 1464-2662
issueIdentifier	5
pageRange	334-344
publicationName	HIV Medicine
startingPage	334
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_06aba5a94448c92faf09747c7e7c67bd
isSupportedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_afd104ee1511b091601c3a095a6036ed http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_a93a1e0f2b5d8775185e2c1c627adccf http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_e6a24aedd32024f5ac6d62b2d5e40cd0 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_a57ae259989db810758369ec702ddf0a
bibliographicCitation	Munderi P, Walker AS, Kityo C, Babiker AG, Ssali F, Reid A, Darbyshire JH, Grosskurth H, Mugyenyi P, Gibb DM, Gilks CF; DART/NORA trial teams. Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts. HIV Med. 2010 May;11(5):334–44. doi: 10.1111/j.1468-1293.2009.00786.x. PMID: 20136661.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d9caefa394c9d5091c79a5dfb97f9bad http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6cc96b86923385c9d721808762c86322 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-9738-5490 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7567fc602f84c0a76a170045998b35d0 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_85de621d8dda75beb8a34f5eb426a244 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2f066cb7d06223e1169a3f113f7bb372 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_de3b147e6a7539d377797ccf4f1b2baa http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1d4e9f892d935d0544f5e5b6a17d0d80 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2de9a028f6d7f4b22676434723f0047e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_68f11c525bd98122e610bf2efd27f301 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_82201ddecbc02fe4b466c2f598c7b383 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a5b741a1e3e71564c22f6caeaaa0a77e
date	2010-04-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/20136661 https://doi.org/10.1111/j.1468-1293.2009.00786.x
isPartOf	https://portal.issn.org/resource/ISSN/1464-2662 https://portal.issn.org/resource/ISSN/1468-1293 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/26808
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48‐week randomized comparison with abacavir/zidovudine/lamivudine in HIV‐infected Ugandan adults with low CD4 cell counts
discusses	http://id.nlm.nih.gov/mesh/M0023377 http://id.nlm.nih.gov/mesh/M0028682 http://id.nlm.nih.gov/mesh/M0019224 http://id.nlm.nih.gov/mesh/M0028255 http://id.nlm.nih.gov/mesh/M0277557 http://id.nlm.nih.gov/mesh/M0023387 http://id.nlm.nih.gov/mesh/M0029429
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D015658Q000188 http://id.nlm.nih.gov/mesh/D015497Q000187 http://id.nlm.nih.gov/mesh/D018894Q000627
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D019562Q000592 http://id.nlm.nih.gov/mesh/D001835Q000187 http://id.nlm.nih.gov/mesh/D019562Q000187 http://id.nlm.nih.gov/mesh/D055118 http://id.nlm.nih.gov/mesh/D015658Q000401 http://id.nlm.nih.gov/mesh/D015224Q000627 http://id.nlm.nih.gov/mesh/D000328 http://id.nlm.nih.gov/mesh/D019829Q000627 http://id.nlm.nih.gov/mesh/D015215Q000627 http://id.nlm.nih.gov/mesh/D015215Q000009 http://id.nlm.nih.gov/mesh/D004311 http://id.nlm.nih.gov/mesh/D014454 http://id.nlm.nih.gov/mesh/D015658Q000821 http://id.nlm.nih.gov/mesh/D019829Q000009 http://id.nlm.nih.gov/mesh/D012367Q000097 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D015658Q000276 http://id.nlm.nih.gov/mesh/D018450 http://id.nlm.nih.gov/mesh/D019259Q000627 http://id.nlm.nih.gov/mesh/D019259Q000009 http://id.nlm.nih.gov/mesh/D018791Q000592 http://id.nlm.nih.gov/mesh/D018894Q000009 http://id.nlm.nih.gov/mesh/D012008 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D016896 http://id.nlm.nih.gov/mesh/D015224Q000009 http://id.nlm.nih.gov/mesh/D004359Q000379 http://id.nlm.nih.gov/mesh/D008875
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9765 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID35370 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_68000b5f90a1d5b5b1a93dbb8aa92d3e http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11167 http://rdf.ncbi.nlm.nih.gov/pubchem/protein/EC_2.7.7.49 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9505 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4463 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID441300 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23480 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60825

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128575040 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128738613 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128324017

Total number of triples: 89.